Persistent COVID ConditionNCT07295483
Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)
An observational study of Persistent COVID Condition, run by Instituto de Investigación Biomédica de Salamanca at 1 site in Spain.
Trial summary
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Persistent COVID Condition
- What is being tested?
- BioICOPER Long COVID Cohort
- How many people
- 400 participants
- Where
- 1 siteSpain
- Study dates
- 9 Feb 2026to Jun 2029
- How long will I take part?
- 4 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults previously enrolled in the BioICOPER study with a clinical diagnosis of long COVID.
Who may be able to join
- Adults ≥18 years old.
- Confirmed previous SARS-CoV-2 infection.
- Diagnosis of long COVID according to WHO criteria.
- Participation in the baseline BioICOPER study.
- Signed informed consent for re-evaluation.
Who cannot join
- Acute illness preventing participation.
- Cognitive or physical impairment limiting data collection.
- Withdrawal of informed consent.
- Age < 18 years old
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Av. de Portugal 83. Planta 2
Salamanca, Salamanca, 37005
Manuel Angel Gómez Marcos, Md, PhD, +346751143551, magomez@usal.es
About this study
Official title: To Analyze the Determining Factors in the Evolution of Subjects Diagnosed With Long COVID at Four Years of Follow-up. BioICOPER Follow-up Study.
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.
The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort.
Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.
Read the detailed description
The study includes a citizen participation component through the IBSAL Citizen Committee for review and dissemination of results. A prospective observational cohort study following 400 adults with a confirmed diagnosis of long COVID, previously enrolled in the BioICOPER baseline study.
Participants will undergo reevaluation four years after their initial inclusion, assessing:
- Clinical symptoms (fatigue, dyspnea, sleep, cognition, nutrition, frailty).
- Lifestyle factors (physical activity, diet, alcohol and tobacco use).
- Vascular structure and function using carotid ultrasound, pulse wave velocity (SphygmoCor®, Vasera®), and retinal imaging.
- Proteomic profiling and quantification of SARS-CoV-2 N and S proteins using ELISA and mass spectrometry.
- Predictive modeling using artificial intelligence (AI) and bioinformatics methods (ESALAB group).
The study will identify biological, vascular, and behavioral determinants of long COVID progression, aiming to build predictive models to support personalized medicine.
- Conditions
- Persistent COVID Condition
- Being tested
- BioICOPER Long COVID Cohort
- Keywords
- Post-acute COVID syndrome, Vascular aging, Proteomics, Biomarkers, Machine learning, Persistent COVID, Artificial Intelligence
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BioICOPER Long COVID CohortOther
This observational cohort includes 400 adult participants previously enrolled in the baseline BioICOPER study (2021-2023), who had a confirmed diagnosis of long COVID (persistent COVID-19) according to WHO criteria.
Participants will undergo a comprehensive four-year follow-up assessment to evaluate clinical evolution, vascular function, and biological markers of disease persistence and recovery.
There is no intervention assigned by the investigators - participants will continue their usual medical care.
The study will observe natural disease progression and its association with biomarkers, vascular measurements, and lifestyle factors.
| Study group | Role | What they receive |
|---|---|---|
| BioICOPER Long COVID Cohort | Adults previously enrolled in the BioICOPER study with a clinical diagnosis of long COVID. Receives: Other: BioICOPER Long COVID Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression of vascular stiffness measured by carotid-femoral pulse wave velocity (cfPWV)
Carotid-femoral pulse wave velocity will be assessed as the gold-standard measure of arterial stiffness, using the SphygmoCor® system. The study will evaluate the longitudinal change in cfPWV between baseline (BioICOPER inclusion) and the 4-year follow-up visit, in order to determine whether long COVID is associated with accelerated vascular aging.
Measured: From baseline to 48-month follow-up
Secondary outcomes (10)
Change in Fatigue Severity Score (FSS)
Fatigue assessed using a validated fatigue scale (Fatigue Severity Scale, FSS). The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue on you. The FSS is a short questionnaire that requires the patient to rate their level of fatigue. The FSS questionnaire contains nine statements that rate the severity of their fatigue symptoms. the patient needs to read each statement and circle a number from 1 to 7, based on how accurately it reflects their condition during the previous week and the extent to which they agree or disagree that the statement applies to them.
A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement.
The goal of this outcome is to determine how fatigue severity evolves and its association with biomarkers and vascular parameters.
Measured: From baseline to 4-year follow-up.
Change in Health-Related Quality of Life (EQ-5D-5L or SF-36)
EQ-5D-5L is a health-related quality of life survey that uses five questions, each with five severity levels, to measure health status across the dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Health state profile: A person's answers create a five-number profile that describes their current health state.
Scoring: This profile can be used to calculate a single index score that represents health-related quality of life. This score ranges from 0 (death) to 1 (full health).
It assesses eight health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health.
The SF-36 survey grades health by scoring responses on eight different health domains, which are then converted to a 0-100 scale where higher scores indicate better health. A score of 100 represents the best possible health in that category, while 0 represents the worst.
Measured: From baseline to 4 years.
Change in Cognitive Function (Montreal Cognitive Assessment, MoCA)
Evaluate cognitive impairment associated with long COVID using the Montreal Cognitive Assessment, which is a 10-minute screening test used to detect mild cognitive impairment in adults. It is a 30-point test that evaluates several cognitive domains, including memory, attention, language, visuospatial skills, executive functions, and orientation. A score of 26 or above is considered a normal result, while lower scores may indicate some level of cognitive dysfunction. The goal of this assesment is to identify determinants of neurocognitive persistence or recovery.
Measured: Baseline to 4 years
Change in Physical Activity (WHO Physical Activity Questionnaire + 7-day pedometer readings)
Objectively and subjectively measure physical activity levels using both WHO Physical Activity Questionnaire and 7-day pedometer readings. The WHO Physical Activity Questionnaire is a 16 question instrument that assesses physical activity participation in three domains (activity at work, travel to and from places, and recreational activities) as well as sedentary behavior. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc. The use of the pedometer only completes the questionnaire, hence both variables need to be meassured simultaneously and interpret them together in order to determine changes in physical activity.
Measured: Baseline to 4 years.
Change in Adherence to the Mediterranean Diet (PREDIMED Questionnaire)
Evaluate diet quality and its relation to metabolic and vascular outcomes. The PREDIMED questionnaire is a screening tool used in the PREDIMED study to assess adherence to the Mediterranean diet. The most common version is a 14-point questionnaire that asks about frequency of consumption of certain foods like olive oil, nuts, fruits, vegetables, and fish, and the limited intake of red meat, butter, and sugary drinks. Participants receive a score of 0 or 1 for each question, and the total score is used to classify their diet as low, moderate, or high in Mediterranean adherence. The goal of this outome is to assess dietary influence on systemic inflammation, endothelial function, and metabolic health.
Measured: Baseline to 4 years.
Change in Body Composition (InBody 230 Bioimpedance Analysis)
The InBody 230 Bioimpedance Analysis is a non-invasive test that measures body composition by sending a mild electrical current through the body. It uses a technique called segmental multifrequency bioelectrical impedance to provide detailed information on body fat, skeletal muscle mass, and body water in the torso, arms, and legs. This analysis offers a more comprehensive picture of your health than a standard scale, providing data like Basal Metabolic Rate (BMR) and Body Mass Index (BMI). The goal od this outcome is to explore links between body composition and cardiovascular risk in long COVID.
Measured: Baseline to 4 years.
Change in Biomarkers of Endothelial and Inflammatory Activity
This Outcome Measure reflects a single assessment in which multiple plasma biomarkers (e.g., ICAM-1, VCAM-1, Endothelin-1, TNF-α, IL-10, and additional cytokines) are quantified within the same measurement framework. All biomarkers are measured using ELISA and proteomic techniques and reported in consistent concentration units (e.g., pg/mL or ng/mL) as appropriate for each assay. Although multiple biomarkers are included, they represent components of one integrated biomarker panel evaluating endothelial and inflammatory activity. No aggregation of different units is performed; instead, each biomarker's concentration is reported separately under this single Outcome Measure to characterize molecular pathways involved in long-term vascular and inflammatory changes in long COVID.
Measured: Baseline to 4 years
Change in Proteomic Profiles
Analysis of proteomic profiling of serum/plasma using advanced mass spectrometry to identify proteins related to fatigue, inflammation, and vascular aging to discover predictive biomarkers for persistent symptoms and disease progression.
Measured: 4 years
SARS-CoV-2 Protein Quantification (N and S Proteins)
In order to explore persistence of viral antigens and relationship with ongoing symptoms and vascular damage, plasma will be qualified using ELISA.
Measured: 4 years
AI-Based Predictive Model Performance
To develop and validate AI-based tools for risk stratification and personalized management using supervised learning (Random Forest, XGBoost, Neural Networks) trained on 70% of the cohort, validated on 30%. The machine learning models will combine clinical, vascular, and proteomic variables to predict disease trajectory.
Measured: Baseline to 4 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2025
- Study start9 Feb 2026
- Primary completionMar 2029 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Persistent COVID ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
- Target duration
- 4 Years
Sponsor and investigators
- Lead sponsor
- Instituto de Investigación Biomédica de Salamanca
- Sponsor type
- University, hospital or other
- Collaborators
- Carlos III Health Institute
- Responsible party
- Sponsor
- Investigators
- Manuel Angel Gomez Marcos, MD, PhD, Principal investigator, Centro Asistencial Universitario de Salamanca (CAUSA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07295483
- Sponsor's protocol ID
- BioICOPER Follow-up Study
- Status last verified
- Mar 2026
- First submitted
- 20 Nov 2025
- Last updated
- 12 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Analyze the Determining Factors in the Evolution of Subjects Diagnosed With Long COVID at Four Years of Follow-up. BioICOPER Follow-up Study.
- ClinicalTrials.gov ID
- NCT07295483
- Acronym / sponsor ID
- BioICOPER Follow-up Study
- Conditions
- Persistent COVID Condition
- Keywords
- Post-acute COVID syndrome, Vascular aging, Proteomics, Biomarkers, Machine learning, Persistent COVID, Artificial Intelligence
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Instituto de Investigación Biomédica de SalamancaUniversity, hospital or other
- Collaborators
- Carlos III Health Institute
- Study start
- 9 Feb 2026 (actual)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 19 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.
The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort.
Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.
Detailed description
The study includes a citizen participation component through the IBSAL Citizen Committee for review and dissemination of results. A prospective observational cohort study following 400 adults with a confirmed diagnosis of long COVID, previously enrolled in the BioICOPER baseline study.
Participants will undergo reevaluation four years after their initial inclusion, assessing:
- Clinical symptoms (fatigue, dyspnea, sleep, cognition, nutrition, frailty).
- Lifestyle factors (physical activity, diet, alcohol and tobacco use).
- Vascular structure and function using carotid ultrasound, pulse wave velocity (SphygmoCor®, Vasera®), and retinal imaging.
- Proteomic profiling and quantification of SARS-CoV-2 N and S proteins using ELISA and mass spectrometry.
- Predictive modeling using artificial intelligence (AI) and bioinformatics methods (ESALAB group).
The study will identify biological, vascular, and behavioral determinants of long COVID progression, aiming to build predictive models to support personalized medicine.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 4 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| BioICOPER Long COVID Cohort | – | Other: BioICOPER Long COVID CohortAdults previously enrolled in the BioICOPER study with a clinical diagnosis of long COVID. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults previously enrolled in the BioICOPER study with a clinical diagnosis of long COVID.
Key inclusion criteria (5 listed)
- Adults ≥18 years old.
- Confirmed previous SARS-CoV-2 infection.
- Diagnosis of long COVID according to WHO criteria.
- Participation in the baseline BioICOPER study.
- Signed informed consent for re-evaluation.
Key exclusion criteria (4 listed)
- Acute illness preventing participation.
- Cognitive or physical impairment limiting data collection.
- Withdrawal of informed consent.
- Age < 18 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BioICOPER Long COVID CohortThis observational cohort includes 400 adult participants previously enrolled in the baseline BioICOPER study (2021-2023), who had a confirmed diagnosis of long COVID (persistent COVID-19) according to WHO criteria. Participants will undergo a comprehensive four-year follow-up assessment to evaluate clinical evolution, vascular function, and biological markers of disease persistence and recovery. There is no intervention assigned by the investigators - participants will continue their usual medical care. The study will observe natural disease progression and its association with biomarkers, vascular measurements, and lifestyle factors. | Other | BioICOPER Long COVID Cohort |
Primary outcome
Progression of vascular stiffness measured by carotid-femoral pulse wave velocity (cfPWV)
Time frame: From baseline to 48-month follow-up
Carotid-femoral pulse wave velocity will be assessed as the gold-standard measure of arterial stiffness, using the SphygmoCor® system. The study will evaluate the longitudinal change in cfPWV between baseline (BioICOPER inclusion) and the 4-year follow-up visit, in order to determine whether long COVID is associated with accelerated vascular aging.
10 secondary outcomes
Change in Fatigue Severity Score (FSS)
Time frame: From baseline to 4-year follow-up.
Change in Health-Related Quality of Life (EQ-5D-5L or SF-36)
Time frame: From baseline to 4 years.
Change in Cognitive Function (Montreal Cognitive Assessment, MoCA)
Time frame: Baseline to 4 years
Change in Physical Activity (WHO Physical Activity Questionnaire + 7-day pedometer readings)
Time frame: Baseline to 4 years.
Change in Adherence to the Mediterranean Diet (PREDIMED Questionnaire)
Time frame: Baseline to 4 years.
Change in Body Composition (InBody 230 Bioimpedance Analysis)
Time frame: Baseline to 4 years.
Change in Biomarkers of Endothelial and Inflammatory Activity
Time frame: Baseline to 4 years
Change in Proteomic Profiles
Time frame: 4 years
SARS-CoV-2 Protein Quantification (N and S Proteins)
Time frame: 4 years
AI-Based Predictive Model Performance
Time frame: Baseline to 4 years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Individual participant dataSharing planned: Yes. Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
Related trials for Persistent COVID Condition
Recruiting
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
COVID-19, Long COVID
Recruiting
PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID
Long COVID
RecruitingPhase 3
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Long COVID, Sars-CoV-2 Infection
Recruiting
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
Hyposmia, COVID-19
RecruitingPhase 2/3
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
Smell Dysfunction, Olfactory Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Manuel Angel Gomez Marcos, MD, PhD principal investigator
Centro Asistencial Universitario de Salamanca (CAUSA)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Persistent COVID Condition, run by Instituto de Investigación Biomédica de Salamanca at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Manuel Angel Gómez Marcos, MD, PhD (+346751143551, magomez@usal.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression of vascular stiffness measured by carotid-femoral pulse wave velocity (cfPWV) (time frame: From baseline to 48-month follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.